7th GUILDFORD ADVANCED PAIN & SYMPTOM MANAGEMENT …€¦ · Tao WW, Tao XM, Song CL. Effects of non-pharmacological supportive care for hot flushes in breast cancer: a meta-analysis.

7th GUILDFORD ADVANCED PAIN &

SYMPTOM MANAGEMENT COURSES

REFERENCE / READING LIST

ALTERNATIVE ROUTES OF ADMINISTRATION

Andrew Dickman

Dickman A, Bickerstaff M, Jackson R, Schneider J, Mason S, Ellershaw

J. Identification of drug combinations administered by continuous subcutaneous

infusion that require analysis for compatibility and stability. BMC Palliat Care. 2017

Mar 23;16(1):22. [Copy of paper available on course website].

Newton DW. Drug incompatibility chemistry. Am J Health Syst Pharm. 2009 Feb

15;66(4):348-57.

UPDATE ON TRANSDERMAL FENTNANYL

David Brooks

Marija Bakovic, Marina Nestic, Davor Mayer. 2015. Death by band-aid: fatal misuse of

transdermal fentanyl patch. International Journal of Legal Medicine 129:1247-1252

Martin Juebner, Mathias Fietzke, Justus Beike, Markus A. Rothschild, Katjia Bender.

2014. Assisted Suicide by fentanyl intoxication due to excessive transdermal

application. International Journal of Legal Medicine 128:949-956

Adam Joseph Trist, Hardeep Sahota, Lucy Williams. 2017. Not so patchy story of

attempted suicide…leading to 24 hours of deep sleep and survival! BMJ Case Reports

1644:126-25

Kazhuliko Koike, Takeshi Terui, Tomokazu Nagasako, Iori Horiuchi, Takayuki

Machino, Toshiro Kusakabe, Yasuo Hirayama, Hiroyoshi Mihara, Michiaki Yamakage,

Junji Kato, Takuji Nishisato, Kunihiko Ishitani. 2016. A new once-a-day fentanyl

citrate patch could be a new treatment option in patients with end-of-dose failure using

a 72-h transdermal fentanyl matrix patch. Support Care Cancer 24:1053-1059

Lesley J. Scott. 2016. Fentanyl Iontophoretic Transdermal System: A Review in Acute

Postoperative Pain. Clin Drug Investigation 36:321-330

Astrid W. Oosten, Joao A. Abrantes, Siv Jonsson, Peter de Bruijn, Evelien J.M. Kuip,

Amilcar Falcao, Cairn C.D. van de Rijt, Ron H.J. Mathijssen. 2016. Treatment with

subcutaneous and transdermal fentanyl: results from a population pharmacokinetic

study in cancer patients. European Journal of Clinical Pharmacology 72:459-467

Daniel T. Barratt, Pai Klepstad, Ola Dale, Stein Kaasa, Andrew A. Somogyi. 2015.

Innate immune signalling genetics of pain, cognitive dysfunction and sickness

symptoms in cancer pain patients treated with transdermal fentanyl. PLoS ONE

10:e0137179

Sudeep Raj Bista, Janet Hardy, Angela Tapuni, Jinlin Fu, Kirsten Gibbons, et al. 2015.

Validation of a fentanyl transdermal adhesion scoring tool for use in clinical practice.

Journal of Pain and Symptom Management 49:934-938

Shao-Zhi Xing, Ying Zhang. 2015. Efficacy and safety of transdermal fentanyl for the

treatment of oral mucositis pain caused by chemoradiotherapy in patients with

esophageal squamous cell carcinoma. Supportive Care in Cancer 23:753-759

Akhila Reddy, Sriram Yennurajalingam, Suresh Reddy, Jimin Wu, Diane Liu, Rony

Dev, Eduardo Bruera. 2016. The opioid rotation ratio from transdermal fentanyl to

“strong” opioids in patients with cancer pain. Journal of Pain and Symptom

Management 51:1040-1045

Nurdan Unlu, Aysegul Bilen, Achmet Ali, Namigar Turgut, Aygen Turkmen, et Al.

2014. The cognitive effects of using transdermal fentanyl in cancer pain. The Journal of

the Turkish Society of Algology 26:126-130

S Derry, C Cole, PJ Wiffen, R Knaggs, D Aldington, R Moore. 2016. Fentanyl for

neuropathic pain in adults. Cochrane Database of Systematic Reviews.

G Hadley, S Derry, R Moore, PJ Wiffen. 2013. Fentanyl for neuropathic pain in adults.

Cochrane Database of Systematic Reviews.

Philip J Wiffen, Bee Wee, Sheena Derry, Rae F Bell, R Andrew Moore. 2017. Opioids

for cancer pain – an overview of Cochrane reviews. Cochrane Database of Systematic

Reviews.

Philip J Wiffen, Sheena Derry, R Andrew Moore. 2014. Impact of morphine, fentanyl,

oxycodone or codeine on patient consciousness, appetite and thirst when used to treat

cancer pain. Cochrane Database of Systematic Reviews.

Dong-Dong Wang, Ting-Ting Ma, Hua-Dong Zhu, Cong-Bin Peng. 2018. Transdermal

fentanyl for cancer pain: trial sequential analysis of 3406 patients from 35 randomized

controlled trials. Journal of Cancer Research and Therapeutics 14:14-21

Leena Choi, Benjamin A Ferrell, Eduard E Vasilevskis, Pratik P Pandharipande,

Rebecca Heltsley, E Wesley Ely, C Michael Stein, Timothy D Girard. 2016. Population

pharmacokinetics of fentanyl in the critically ill. Critical Care Medicine 44:64-72

OPIOID ADVERSE EFFECTS - NOT THE “USUAL SUSPECTS”!

Andrew Davies

Vervloet D, Durham S. Adverse reactions to drugs. British Medical Journal 1998; 316:

1511-4.

Oosten AW, Oldenmenger WH, Mathijssen RH et al. A systematic review of

prospective studies reporting adverse events of commonly used opioids for cancer-

related pain: a call for the use of standardized outcome measures. Journal of Pain 2015;

16: 935-946. [Copy of paper available on course website].

Potter J, Hami F, Bryan T, Quigley C. Symptoms in 400 patients referred to palliative

care services: prevalence and patterns. Palliative Medicine 2003; 17: 310-4.

Shorthose K, Davies A. Symptom prevalence in palliative care. Palliative Medicine

2003; 17: 723-4.

Fountain A. Visual hallucinations: a prevalence study among hospice inpatients.

Palliative Medicine 2001; 15: 19-25.

Davies AN, Quinn T. Opioid-related musical hallucinations. Journal of Pain and

Symptom Management 2005; 29: 327-8. [Copy of paper will be available on course

website].

Davies AN, Patel SD, Gregory A, Lee B. Observational study of sleep disturbance in

advanced cancer. BMJ Supportive and Palliative Care 2017; 7: 435-40. [Copy of paper

will be available on course website].

Cheatle MD, Webster LR. Opioid therapy and sleep disorders: risks and mitigation

strategies. Pain Medicine 2015; 16; S22-6. [Copy of paper available on course website].

ACUPUNCTURE FOR PAIN RELIEF

Graham Leng

Wu X, Chung VC, Hui EP, Ziea ET, Ng BF, Ho RS, Tsoi KK, Wong SY, Wu JC.

Effectiveness of acupuncture and related therapies for palliative care of cancer:

overview of systematic reviews. Sci Rep. 2015 Nov 26;5:16776 [Copy of paper

available on course website].

Leng G. Use of acupuncture in hospices and palliative care services in the UK.

Acupunct Med. 2013 Mar;31(1):16-22 [Copy of paper available on course website].

Standish LJ, Kozak L, Congdon S. Acupuncture is underutilized in hospice and

palliative medicine. Am J Hosp Palliat Care. 2008 Aug-Sep;25(4):298-308

White A. The safety of acupuncture – evidence from the UK. Acupunct Med 2006;

24(Suppl):S53-57

Chiu HY, Hsieh YJ, Tsai PS. Systematic review and meta-analysis of acupuncture to

reduce cancer-related pain. Eur J Cancer Care (Engl). 2017 Mar;26(2)

Chen L, Lin CC, Huang TW, Kuan YC, Huang YH, Chen HC, Kao CY, Su CM, Tam

KW. Effect of acupuncture on aromatase inhibitor-induced arthralgia in patients with

breast cancer: A meta-analysis of randomized controlled trials. Breast. 2017

Jun;33:132-138

Hu C, Zhang H, Wu W, Yu W, Li Y, Bai J, Luo B, Li S. Acupuncture for Pain

Management in Cancer: A Systematic Review and Meta-Analysis. Evidence-Based

Complementary and Alternative Medicine Volume 2016, Article ID 1720239 [Copy of

paper available on course website].

Vickers AJ, Vertosick EA, Lewith G, MacPherson H, Foster NE, Sherman KJ, Irnich

D, Witt CM, Linde K; Acupuncture Trialists' Collaboration. Acupuncture for Chronic

Pain: Update of an Individual Patient Data Meta-Analysis. J Pain. 2018 May;19(5):455-

474

Franconi G, Manni L, Schröder S, Marchetti P, Robinson N. A systematic review of

experimental and clinical acupuncture in chemotherapy-induced peripheral neuropathy.

Evid Based Complement Alternat Med. 2013;2013:516916

Lee A, Chan SK, Fan LT. Stimulation of the wrist acupuncture point PC6 for

preventing postoperative nausea and vomiting. Cochrane Database Syst Rev. 2015 Nov

2;(11):CD003281

Ezzo J, Vickers A, Richardson MA, Allen C, Dibble SL, Issell B, Lao L, Pearl M,

Ramirez G, Roscoe JA, Shen J, Shivnan J, Streitberger K, Treish I, Zhang G.

Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting. J Clin

Oncol. 2005 Oct 1;23(28):7188-98

Vickers AJ. Can acupuncture have specific effects on health? A systematic review of

acupuncture antiemesis trials. J R Soc Med. 1996 Jun;89(6):303-11

Coyle ME, Shergis JL, Huang ET, Guo X, Di YM, Zhang A, Xue CC. Acupuncture

therapies for chronic obstructive pulmonary disease: a systematic review of

randomized, controlled trials. Altern Ther Health Med. 2014 Nov-Dec;20(6):10-23

Simcock R, Fallowfield L, Monson K, Solis-Trapala I, Parlour L, Langridge C, Jenkins

V; ARIX Steering Committee. ARIX: a randomised trial of acupuncture v oral care

sessions in patients with chronic xerostomia following treatment of head and neck

cancer. Ann Oncol. 2013 Mar;24(3):776-83

Tao WW, Tao XM, Song CL. Effects of non-pharmacological supportive care for hot

flushes in breast cancer: a meta-analysis. Support Care Cancer. 2017 Jul;25(7):2335-

2347

Chien TJ, Hsu CH, Liu CY, Fang CJ. Effect of acupuncture on hot flush and

menopause symptoms in breast cancer- A systematic review and meta-analysis. PLoS

One. 2017 Aug 22;12(8)

Chen YP, Liu T, Peng YY, Wang YP, Chen H, Fan YF, Zhang L. Acupuncture for hot

flashes in women with breast cancer: A systematic review. J Cancer Res Ther. 2016

Apr-Jun;12(2):535-42

Forde JC, Jaffe E, Stone BV, Te AE, Espinosa G, Chughtai B. The role of acupuncture

in managing overactive bladder; a review of the literature. Int Urogynecol J. 2016

Nov;27(11):1645-1651

Zhang Y, Lin L, Li H, Hu Y, Tian L. Effects of acupuncture on cancer-related fatigue: a

meta-analysis. Support Care Cancer. 2018 Feb;26(2):415-425

Filshie J, Hester J. Guidelines for providing acupuncture treatment for cancer patients –

a peer-reviewed sample policy document. Acupunct Med 2006;24(4):172-182

Filshie J. Safety Aspects of Acupuncture in Palliative Care. Acupunct Med

2001;19(2):117-122

National Guidelines for the Use of Complementary Therapies in Supportive and

Palliative Care. Tavares M. The Prince of Wales’s Foundation for Integrated Health

and the National Council for Hospice and Specialist Palliative Care Services, 2003

British Medical Acupuncture Society

www.medical-acupuncture.co.uk

Acupuncture in Medicine journal

https://aim.bmj.com

BMAS training in acupuncture

www.medical-acupuncture.co.uk/TrainingEducation/Acupuncturetraining.aspx

WHAT ELSE IS NEW (PAIN)?

Andrew Davies

Smith HS. Potential analgesic mechanisms of acetaminophen. Pain Physician 2009; 12:

269-80. [Copy of paper available on course website].

Wiffen PJ, Derry S, Moore RA et al. Oral paracetamol (acetaminophen) for cancer

pain. Cochrane Database of Systematic Reviews 2017, Issue 7. Art. No.: CD012637.

[Copy of paper available on course website].

Davies AN, Vriens J, Webber K et al. An observational study of paracetamol

(acetaminophen) deprescribing in patients with cancer pain receiving opioids for

moderate-to-severe pain. Medycyna Paliatywna w Praktyce 2017; 11: 133-7. [Copy of

paper available on course website].

Axelsson B, Stellborn P, Strom G. Analgesic effect of paracetamol on cancer related

pain in concurrent strong opioid therapy. A prospective clinical study. Acta Oncologica

2008; 47: 891-5.

Jibril F, Sharaby S, Mohamed A et al. Intravenous versus oral acetaminophen for pain:

systematic review of current evidence to support clinical decision-making. Canadian

Journal of Hospital Pharmacy 2015; 68: 238-47.

Raffa RB, Pawasauskas J, Pergolizzi JV et al. Pharmacokinetics of oral and intravenous

paracetamol (acetaminophen) when co-administered with intravenous morphine in

healthy adult subjects. Clinical Drug Investigation 2018; 38: 259-68.

Carr AC, McCall C. The role of vitamin C in the treatment of pain: new insights.

Journal of Translational Medicine 2017; 15: 77.

Helde-Frankling M, Bjorkhem-Bergman L. Vitamin D in pain management.

International Journal of Molecular Sciences. [Copy of paper available on course

website].

Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health.

American Journal of Clinical Nutrition 2008; 87(Suppl): 1080S-6S. [Copy of paper

available on course website].

Palacios C, Gonzalez L. Is vitamin D deficiency a major global public health problem.

Journal of Steroid Biochemistry and Molecular Biology 2014; 144 Part A: 139-45.

Bergman P, Sperneder S, Holjer J et al. Low vitamin D levels are associated with

higher opioid dose in palliative cancer patients - results from an observational study in

Sweden. Plos One 2015; 10: e0128223.

Helde-Frankling M, Holjer J, Begqvist L et al. Vitamin D supplementation to palliative

cancer patients shows positive effects on pain and infections - results from a matched

case-control study. Plos One 2017; 12: e0184208. [Copy of paper available on course

website].

PAIN - WHAT IT DOES TO US, AND WHAT CAN WE DO ABOUT IT?

Tony Dickenson

Bannister K, Kucharczyk M, Dickenson AH. Hopes for the future of pain. Pain Ther

2017; 6: 117-28. [Copy of paper available on course website].

Colloca L, Ludman T, Bouhassira D et al. Neuropathic pain. Nat Rev Dis Primers

2017; 3: 17002. [Copy of paper available on course website].

Falk S, Dickenson AH. Pain and nociception: mechanisms of cancer-induced bone

pain. J Clin Oncol 2014; 32: 1647-54.

SYMPTOM ASSESSMENT

Jo Thompson

Ahmed N, Ahmedzai S, Collins K et al. Holisitic assessment of supportive and

palliative care needs: the evidence for routine, systematic questioning. BMJ Supportive

and Palliative Care 2014; 0: 1-9

Aslakson R, Dy S, Wilson R et al. Patient and caregiver-reported assessment tools for

palliative care: Summary of the 2017 agency for healthcare research and quality

technical brief. Journal of Pain and Symptom Management 2017; 4: 961-973.

Barresi M, Shadbolt B, Byrne D et al. The development of the Canberra symptom

scorecard: a tool to monitor the physical symptoms of patients with advanced tumours.

BMC Cancer 2003; 3: 1-9.

Browner I, Smith T. Symptom assessment in elderly cancer patients receiving palliative

care. Annals of Oncology 2013; 23:125-129.

Chang V, Hwang S, Kasimis B et al. Shorter symptom assessment instruments: the

Condensed Memorial Symptom Assessment Scale (CMSAS). Cancer Investigation

2004; 22: 526-536.

Chang V, Hwang S, Feuerman M et al. Validation of the Edmonton symptom

assessment scale. Cancer 2000; 88: 2164-2171.

Chang V, Hwang S, Feuerman M et al. The Memorial Symptom Assessment Scale

Short Form (MSAS-SF). Cancer 2000; 89: 1162-1171

Clement S, Woodgate R, Degner L. Symptom distress in adult patients with cancer.

Cancer Nursing 1997; 20: 236-243

Ewing G, Rogers M, Barclay S et al. Palliative care in primary care: a study to

determine whether patients and professionals agree on symptoms. British Journal of

General Practice 2006; 56: 27-34

Fetz K, Vogt H, Ostermann T et al. Evaluation of the palliative symptom burden score

(PSBS) in a specialised palliative care unit of a university medical centre – a

longitudinal study. BMC Palliative Care 2018; 1-13. [Copy of paper available on

course website].

Homsi J, Walsh D, Rivera Net al. Symptom evaluation in palliative medicine: patient

report vs systematic assessment. Supportive Care in Cancer 2006; 14: 444-453.

Horton R. Differences in assessment of symptoms and quality of life between patients

with advanced cancer and their specialist palliative care nurses in a home care setting.

Palliative Medicine 2002; 16: 488-494

Hui D, Bruera E. The Edmonton symptom assessment system 25 years later: Past,

present and future developments. Journal of Pain and Symptom Management 2017; 53:

630-643.

Kirkova J, Davis M, Walsh D et al. Cancer symptom assessment instruments: A

systematic review. Journal of Clinical Oncology 2006; 24: 1459-1473.

Kwok Oi-Ling D, Kam-Hung D. Symptom distress as rated by advanced cancer

patients, caregivers and physicians in the last week of life. Palliative Medicine 2005;

19: 228-233

Lam W, Law C, Fu Y et al. New insights in symptom assessments: The chinese

versions of the memorial symptom assessment scale short form (MSAS-SF) and the

condensed MSAS (CMSAS). Journal of pain and Symptom Management 2008; 36:

584-595.

Lobchuk M. The memorial symptom assessment scale: Modified for use in

understanding family caregivers’ perceptions of cancer patients’ symptom experiences.

Journal of Pain and Symptom Management 2003; 26: 644-654.

McPherson C, Wilson K, Lobchuk M et al. Family caregivers’ assessment of symptoms

in patients with advanced cancer: Concordance with patients and factors affecting

accuracy. Journal of Pain and Symptom Management 2008; 35: 70-82.

Mercadante S, Adile C, Lanzetta G et al. Personalised symptom goals and patient

global impression on clinical changes in advanced cancer patients. The Oncologist

2018; 23: 1-8

Narducci F, Grande R, Mentuccia L et al. Symptom improvement as a prognostic factor

for survival in cancer patients undergoing palliative care: a pilot study. Supportive Care

in Cancer 2012; 20: 1221-1226

Nekolaichuk C, Bruera E, Spachynski K et al. A comparison of patient and proxy

symptom assessments in advanced cancer patients. Palliative Medicine 1999; 13: 311-

323

Nekolaichuk C, Maguire T, Suarez-Almazar M et al. Assessing the reliability of

patient, nurse and family caregiver symptom ratings in hospitalised advanced cancer

patients. Journal of Clinical Oncology; 17: 3621-3630

Oldenmenger W, de Raaf P, Klerk C et al. Cut points on 0-10 numeric rating scales for

symptoms included in the Edmonton Symptom Assessment Scale in cancer patients: A

systematic review. Journal of Pain and Symptom Management 2013; 45: 1083-1093

Portenoy R, Thaler H, Kornblith A et al. The memorial symptom assessment scale: an

instrument for the evaluation of symptom prevalence, characteristics and distress.

European Journal of Cancer 1994; 30: 1326-1336

Reilly C, Bruner d, Mitchell S et al. A literature synthesis of symptom prevalence and

severity in persons receiving active cancer treatment. Supportive Care in Cancer 2013;

21: 1525-1550

Rhondali W, Hui D, Kim S et al. Association between patient reported symptoms and

nurses clinical impressions in cancer patients admitted to an acute palliative care unit.

Journal of Palliative Medicine 2012; 15: 301-307

Richardson L, Jones G. A review of the reliability and validity of the Edmonton

symptom assessment system. Current Oncology 2009; 16: 53-64

Ripamonti C, Bandieri E, Pessi M et al. The Edmonton symptom assessment system

(ESAS) as a screening tool for depression and anxiety in non-advanced patients with

solid or haematological malignancies on cure or follow-up. Supportive Care in Cancer

2014; 22: 783-793

Seow B, Sussman J, Martelli-Reid L et al. Do high symptom scores trigger clinical

actions? An audit after implementing electronic symptom screening. Journal of

Oncology Practice 2012; 8: 142-148 [Copy of paper available on course website].

Schulman-Green D, Cherlin E, McCorkle R et al. Benefits and challenges in use of a

standard symptom assessment instrument in hospice. Journal of Palliative Medicine

2010; 13: 155-159

Sharp J, Gough K, Pascoe M et al. The modified memorial symptom assessment scale

short form: a modified response format and rational scoring rules. Quality of Life

Research 2018;

Sikorskii A, Wyatt G, Tamkus D et al. Concordance between patient reports of cancer

related symptoms and medical records documentation. Journal of Pain and Symptom

Management 2012; 44: 362-372

Spaner D, Caraiscos V, Muystra C et al. Use of standardised assessment tools to

improve the effectiveness of palliative care rounds: A quality improvement initiative.

Journal of Palliative Care 2017; 32: 134-140

Stewart-Knight K, Parry R, Abey A et al. Does the distress thermometer work? A

systematic review of the evidence for its use and validity. BMJ Supportive and

Palliative Care 2012; 2(supp 1): A1-A120

Strasser F, Blum D, von Moos R et al. The effect of real time electronic monitoring of

patient-reported symptoms and clinical syndromes in outpatient workflow of medical

oncologists: E-MOSAIC, a multicentre cluster-randomised phase III study (SAKK

95/06). Annals of Oncology 2016; 27: 324-332

Stromgren A, Sjogren P, Goldschmidt D et al. Symptom priority and course of

symptomatology in specialised palliative care. Journal of Pain and Symptom

Management 2006; 31: 199-206

Teunissen S, Wesker W, Kruitwagen C et al. Symptom prevalence in patients with

incurable cancer: A systematic review. Journal of Pain and Symptom Management

2007; 34: 94-104

Tranmer J, Heyland D, Dudgeon D et al. measuring the symptom experience of

seriously ill cancer and noncancer hospitalised patients near the end of life with the

memorial symptom assessment scale. Journal of Pain and Symptom Management 2003;

25: 420-429

White C, McMullan D, Doyle J. “Now that you mention it, doctor…” Symptom

reporting and the need for systematic questioning in a specialised palliative care unit.

Journal of Palliative Medicine 2009; 12: 447-450

ORAL PROBLEMS

Andrew Davies

Davies A, Finlay I. Oral Care in Advanced Disease. Oxford: Oxford University Press;

2005.

Davies AN, Epstein JB. Oral Complications of Cancer and its Management. Oxford:

Oxford University Press; 2010.

Davies AN. Oral care. In: Cherny N, Fallon M, Kaasa S, Portenoy R, Currow D,

editors. Oxford textbook of Palliative Medicine, 5th edition. Oxford: Oxford University

Press; 2015.

OLD VS NEW: HALOPERIDOL VS OLANZAPINE

Andrew Dickman

Prommer E. Olanzapine: palliative medicine update. Am J Hosp Palliat Care.

2013;30(1):75-82.

Digges M, Hussein A, Wilcock A, Crawford GB, Boland JW, Agar MR, et al.

Pharmacovigilance in Hospice/Palliative Care: Net Effect of Haloperidol for Nausea or

Vomiting. J Palliat Med. 2018;21(1):37-43.

Walsh D, Davis M, Ripamonti C, Bruera E, Davies A, Molassiotis A. 2016 Updated

MASCC/ESMO consensus recommendations: Management of nausea and vomiting in

advanced cancer. Support Care Cancer. 2017;25(1):333-40.

Van Der Vorst M, Neefjes ECW, Boddaert MSA, Verdegaal BATT, Beeker A et

al. Efficacy and side effect profile of olanzapine versus haloperidol for symptoms of

delirium in hospitalized patients with advanced cancer: A multicenter, investigator-

blinded, randomized, controlled trial (RCT). J Clin Oncol 2017;35(31 suppl):231-231.

Hui D, Dev R, Bruera E. Neuroleptics in the management of delirium in patients with

advanced cancer. Curr Opin Support Palliat Care. 2016;10(4):316-323. [Copy of paper

available on course website].

Meyer JM, Simpson GM. From chlorpromazine to olanzapine: a brief history of

antipsychotics. Psychiatr Serv. 1997;48(9):1137-9. [Copy of paper available on course

website].

Beach SR, Celano CM, Sugrue AM, Adams C, Ackerman MJ, Noseworthy PA, et al.

QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year

Update. Psychosomatics. 2018;59(2):105-22.

CORTICOSTEROIDS - BENEFITS AND RISKS

Kath Webber

Stina Dinsen, Bo Baslund, Marianne Klose, Aase Krogh Rasmussen, Lennart Friis-

Hansen, Linda Hilsted, and Ulla Feldt-Rasmussen. Why glucocorticoid withdrawal may

sometimes be as dangerous as the treatment itself. European Journal of Internal

Medicine, 2013 vol. 24 (8) pp. 714-720.

Alison Haywood, Phillip Good, Sohil Khan, Aurelia Leupp, Sue Jenkins-Marsh, Kirsty

Rickett, and Janet R Hardy. Corticosteroids for the management of cancer-related pain

in adults. Cochrane Database of Systematic Reviews, 2015 vol. 41 (4) p. 459.

David Hui, Kelly Kilgore, Susan Frisbee-Hume, Minjeong Park, Anne Tsao, Marvin

Delgado-Guay, Charles Lu, William William Jr., Katherine Pisters, George Eapen,

Frank Fossella, Sapna Amin, and Eduardo Bruera. Dexamethasone for Dyspnea in

Cancer Patients: A Pilot Double-Blind, Randomized, Controlled Trial. J Pain Symptom

Manage, 2016 vol. 52 (1) pp. 8-16.e1.

Jessica L Hwang and Roy E Weiss. Steroid-induced diabetes: a clinical and molecular

approach to understanding and treatment. Diabetes Metab Res Rev, 2014 vol. 30 (2) pp.

96-102.

Leon Margolin, Doris K Cope, Rachel Bakst-Sisser, and Joshua Greenspan. The Steroid

Withdrawal Syndrome: A Review of the Implications, Etiology, and Treatments. J Pain

Symptom Manage, 2007 vol. 33 (2) pp. 224-228.

Ollie Minton, Alison Richardson, Michael Sharpe, Matthew Hotopf, and Patrick Stone.

Drug therapy for the management of cancer-related fatigue. Cochrane Database of

Systematic Reviews, 2010 vol. 1 (3) p. 140.

Ørnulf Paulsen, Pål Klepstad, Jan Henrik Rosland, Nina Aass, Eva Albert, Peter Fayers,

and Stein Kaasa. Efficacy of Methylprednisolone on Pain, Fatigue, and Appetite Loss

in Patients With Advanced Cancer Using Opioids: A Randomized, Placebo-Controlled,

Double-Blind Trial. Journal of Clinical Oncology, 2014 vol. 32 (29) pp. 3221-3228.

D Tomlinson, P D Robinson, S Oberoi, D Cataudella, N Culos-Reed, H Davis, N

Duong, F Gibson, M Götte, P Hinds, S L Nijhof, P Van der Torre, S Cabral, L L

Dupuis, and L Sung. Pharmacologic interventions for fatigue in cancer and

transplantation: a meta-analysis. Curr Oncol, 2018 vol. 25 (2) p. 152.

Petra Vayne-Bossert, Alison Haywood, Phillip Good, Sohil Khan, Kirsty Rickett, and

Janet R Hardy. Corticosteroids for adult patients with advanced cancer who have

nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery). Cochrane

Database of Systematic Reviews, 2017 vol. 28 (4) p. 381.

UPDATE ON BISPHOSPONATES / DENOSUMAB

Sarah Cox

Dietzek A, Connelly K, Cotugno M, et al. (2015) Denosumab in hypercalcemia of

malignancy: a case series. J Oncol Pharm Pract; 21:143-7.

Karuppiah D, Thanabalasingham G, Shine B, et al. (2014) Refractory hypercalcaemia

secondary to parathyroid carcinoma: response to high-dose denosumab. Eur J

Endocrinol; 171:K1-5.

Adhikaree J, Newby Y, Sundar S. (2014) Denosumab should be the treatment of choice

for bisphosphonate refractory hypercalcaemia of malignancy. BMJ Case Rep; 2014.

Hu MI, Glezerman IG, Leboulleux S, et al. (2014) Denosumab for treatment of

hypercalcemia of malignancy. J Clin Endocrinol Metab; 99:3144-52.

Coleman R, Body JJ, Aapro M, et al. (2014) Bone health in cancer patients: ESMO

Clinical Practice Guidelines. Ann Oncol; 25 Suppl 3:iii124-37.

National Institute for Health and Care Excellence (2014) Prostate cancer; diagnosis and

management (NICE Guideline 175).

Available at: https://www.nice.org.uk/guidance/cg175

National Institute for Health and Care Excellence (2012) Denosumab for the

prevention of skeletal-related events in adults with bone metastases from solid tumours

(NICE guidance TA265)

Available at; https://www.nice.org.uk/guidance/ta265

Fizazi K, Carducci M, Smith M, et al. (2011) Denosumab versus zoledronic acid for

treatment of bone metastases in men with castration-resistant prostate cancer: a

randomised, double-blind study. Lancet; 377:813-22.

O’Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N Goodwin A. (2017)

Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev

Oct 30;10:CD003474. doi: 10.1002/14651858.CD003474.pub4.

Stopeck AT, Lipton A, Body JJ, et al. (2010) Denosumab compared with zoledronic

acid for the treatment of bone metastases in patients with advanced breast cancer: a

randomized, double-blind study. J Clin Oncol; 28:5132-9.

Barrett-Lee P, Casbard A, Abraham J et al. (2014) Oral Ibandronic acid versus

intravenous zoledronic acid in treatment of bone metastases from breast cancer: a

randomised, open label, non-inferiority phase 3 trial. Lancet Oncol; 15:114-22.

Van Poznak C, Somerfield MR, Barlow WE, et al. (2017) Role of bone-modifying

agents in metastatic breast cancer: An American Society of Clinical Oncology–Cancer

Care Ontario focused guideline update. J Clin Oncol; 35:3978-86.

Shapiro CL, Moriaty JP, Dusetzina S et al (2017) Cost- effectiveness analysis of

monthly zolendronic acid, zolendronic acid every 3 months, and monthly denosumab in

women with breast cancer and skeletal metasteses: CALGB 70604. J Clin Oncol;

35:3949-55.

Himelstein AL, Foster JC, Khatcheressian JL, et al. (2017) Effect of longer-interval vs

standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a

randomized clinical trial. JAMA; 317:48-58.

Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. (2017) Bisphosphonates in

multiple myeloma: an updated network meta-analysis. Cochrane Database Syst. Rev

Dec 18;12:CD003188. doi: 10.1002/14651858.CD003188.pub4.

P Hadji, R E. Coleman, C Wilson et al. (2016) Adjuvant bisphosphonates in early

breast cancer: consensus guidance for clinical practice from a European Panel. Ann

Oncol; 27:379-90.

NICE evidence summary (ES15) Published date July 2017. Early breast cancer

(preventing recurrence and improving survival): adjuvant bisphosphonates

Early Breast Cancer Trialists' Collaborative Group (2015) Adjuvant bisphosphonate

treatment in early breast cancer: meta-analyses of individual patient data from

randomised trials. Lancet; 386:1353-61.

Dhesy-Thind S, Fletcher GG, Blanchette PS et al (2017) Use of adjuvant

bisphosphonates and other bone-modifying agents in breast cancer: A Cancer Care

Ontario and American Society of Clinical Oncology Clinical Practice Guideline. J Clin

Oncol; 35:2062-81

MHRA/CHM advice: Denosumab: minimising the risk of osteonecrosis of the jaw;

monitoring for hypocalcaemia—updated recommendations (September 2014) and

Denosumab: osteonecrosis of the jaw—further measures to minimise risk (July 2015)

MHRA/CHM advice: Denosumab: reports of osteonecrosis of the external auditory

canal (June 2017)

MHRA/CHM advice: Denosumab (Xgeva®) for giant cell tumour of bone: risk of

clinically significant hypercalcaemia following discontinuation (June 2018)

MHRA/CHM advice: Denosumab (Xgeva®) for advanced malignancies involving

bone: study data show new primary malignancies reported more frequently compared to

zoledronic acid (zoledronate) (June 2018)

VENOUS THROMBOEMBOLISM

Simon Noble

Carrier M, Khorana AA, Zwicker JI, Noble S, Lee AYY Management of challenging

cases of patients with cancer-associated thrombosis including recurrent thrombosis and

bleeding: guidance from the SSC of the ISTH. Journal Thrombosis and Haemostasis

2013 September; 11(9) 1760-65

Lloyd AJ, Dewilde S, Noble S, Reimer E, Lee AYY. What impact does venous

thromboembolism and bleeding have on cancer patients' quality of life? Value Health.

2018 Apr;21(4):449-455. doi: 10.1016

Font C, Garcia-Fernandez T, Nelson A, Prout H, Noble S. Patients' Experiences of

LIving with CANcer associated thrOmbosis in Spain (PELICANOS). Supportive Care

in Cancer 2018. Apr 7. doi: 10.1007/s00520-018-4174-5.

Samuelson Bannow BT, Lee A, Khorana AA, Zwicker JI, Noble S, Ay C, Carrier M.

"Management of cancer-associated thrombosis in patients with thrombocytopenia:

guidance from the SSC of the ISTH" Journal Thrombosis and Haemostasis. 2018 Apr

2. doi: 10.1111/jth.14015

Noble S. Are new anticoagulants a safe and reasonable alternative to low molecular

heparins? Thromb Res. 2018 Apr;164 Suppl 1:S157-S161.

Khorana AA, Noble S, Lee AYY, Soff G, Meyer G, O'Connell C, Carrier M. Role of

direct oral anticoagulants in the treatment of cancer-associated venous

thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2018 Jun

29. doi: 10.1111/jth.14219

G.E. Raskob, N. van Es, P. Verhamme, M. Carrier, M. Di Nisio, D. Garcia, et al.

Edoxaban for the treatment of cancer-associated venous thromboembolism, N. Engl. J.

Med. (2017),

Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn JA,

Lyman GH, Hutchinson C, MacCallum P, Kakkar A, Hobbs FDR, Petrou S, Dale J,

Poole CJ, Maraveyas A, Levine M. Comparison of an Oral Factor Xa Inhibitor With

Low Molecular Weight Heparin in Patients With Cancer With Venous

Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018

Jul 10;36(20):2017-2023.

WHAT ELSE IS NEW (SYMPTOMS)

Andrew Davies

Simon ST, Weingartner V, Higginson IJ et al. Definition, categorization, and

terminology of episodic breathlessness: consensus of an international Delphi survey.

Journal of Pain and Symptom Management 2014; 47: 828-38.

Simon ST, Weingartner V, Higginson et al. “I can breathe again!” Patients’ self-

management strategies for episodic breathlessness in advanced disease, derived from

qualitative interviews. Journal of Pain and Symptom Management 2016; 52: 228-34.

Jatoi A, Qin R, Satele D et al. “Enjoy a glass of wine before eating”: a randomized trial

to text the orexigenic effects of this advice in advanced cancer patients. Supportive

Care in Cancer 2016; 24: 3739-46.

Kerr D. Alcohol and palliative care. Palliative Medicine 1992; 6: 185-201.

Twycross RG, Gilhooley RA. Euphoriant elixir. British Medical Journal 1973 4: 552.

TERMINAL SEDATION - THE RIGHTS AND WRONGS!

Craig Gannon

Lomas C, ‘Dying patients denied pain relief because of legal fears’, Nursing Times, 18

May, 2010

Willis D, Gannon C, Harlow T, Idris Baker I, & George R ‘A response to L. Anquinet

et al.’s article on terminal sedation’ Palliative Medicine, 2014; pp. 367-368

Raus K; Sterckx S, ‘How defining clinical practices may influence their evaluation: the

case of continuous sedation at the end of life’ Journal of Evaluation in Clinical Practice,

2016; 22(3):425-32

Royal College of Physicians ‘Prolonged disorders of consciousness: National clinical

guidelines’ London, RCP, 2013

Glannon W. ‘The Value and Disvalue of Consciousness’ Cambridge Quarterly of

Healthcare Ethics, 2016; 25(4):600-12

Cohen-Almagor & Ely, ‘Euthanasia and palliative sedation in Belgium’, BMJ Support

Palliative Care, 2018; 8(3): 307-313

Bruinsma SM; van der Heide A; van der Lee ML; Vergouwe Y; Rietjens JA. ‘No

Negative Impact of Palliative Sedation on Relatives' Experience of the Dying Phase and

Their Wellbeing after the Patient's Death: An Observational Study’ PLoS ONE, 2016;

11(2):e0149250

Beller EM, van Driel M, McGregor L, Truong S, Mitchell G. Palliative

pharmacological sedation for terminally ill adults. Cochrane Database of Systematic

Reviews 2015, Issue 1. Art. No.: CD010206. DOI: 10.1002/14651858.CD010206.pub2

Agar MR, Lawlor PG, Quinn, S, l Draper B, Caplan GA; Rowett D, Sanderson C,

Hardy J, Le B, Eckermann S, McCaffrey N, Devilee L, Fazekas B, Hill M, & Currow

DC, ‘Efficacy of Oral Risperidone, Haloperidol, or Placebo for Symptoms of Delirium

Among Patients in Palliative Care A Randomized Clinical Trial’ JAMA Intern Med,

2017; 177(1): 34-42

van Deijck RH; Hasselaar JG; Verhagen SC; Vissers KC; Koopmans RT ‘Patient-

Related Determinants of the Administration of Continuous Palliative Sedation in

Hospices and Palliative Care Units: A Prospective, Multicenter, Observational Study’

Journal of Pain & Symptom Management, 2016; 51(5):882-9

Twycross R, ‘Second thoughts about palliative sedation’ Evidence Based Nursing,

2017; 20(2):33-34

Davies J, Willis D & George R ‘The double effect is no doctrine: it’s a reflective tool

part I’ EJPC, 2017; 24 (4): 178-182

Wheeler R, ‘Doctrine of Double Effect’, Bulletin of the Royal College of Surgeons of

England, 2016; 98(5):220-220